KH658
Sponsors
Chengdu Origen Biotechnology Co., Ltd.
Conditions
Age-Related Macular DegenerationAge-related Macular Degeneration
Phase 1
Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
RecruitingNCT06458595
Start: 2024-06-28End: 2026-12-28Target: 44Updated: 2024-11-29
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
Active, not recruitingNCT06825858
Start: 2025-04-07End: 2027-03-31Target: 9Updated: 2026-01-08